2025-08855NoticeWallet

FDA Patent Clock Starts Ticking for ELAHERE's Review Period

Published Date: 5/19/2025

Notice

Summary

The FDA has officially set the review period for ELAHERE, a human biological product, which helps decide if its patent can be extended. This affects the company behind ELAHERE and anyone interested in patent timing or drug development. If you think the dates are wrong or want to challenge the applicant’s effort during review, you’ve got until mid-2025 to speak up—so don’t miss your chance!

Analyzed Economic Effects

4 provisions identified: 4 benefits, 0 costs, 0 mixed.

Regulatory review period set at 3,867 days

FDA determined the regulatory review period for ELAHERE is 3,867 days in total: 3,635 days for the testing phase and 232 days for the approval phase. FDA verified the key dates used: IND effective April 15, 2012; BLA initially submitted March 28, 2022; BLA approved November 14, 2022.

Applicant's requested patent extension lengths

ImmunoGen, Inc. submitted patent term restoration applications for ELAHERE and in those applications seeks patent term extensions of 1,149 days; 1,677 days; 1,733 days; 1,740 days; or 1,775 days. FDA notes that the USPTO will apply statutory limitations when calculating the actual extension.

ELAHere approved under accelerated approval

FDA approved ELAHERE (mirvetuximab soravtansine-gynx) for adult patients with folate receptor alpha (FRα)–positive, platinum‑resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens. The approval (granted November 14, 2022) is under accelerated approval based on tumor response rate and durability of response, and continued approval may depend on a confirmatory trial.

Opportunity to challenge dates and due diligence

Anyone who believes the published dates are incorrect may submit comments and ask for a redetermination by July 18, 2025, and any interested person may petition FDA about whether the applicant acted with due diligence by November 17, 2025. The notice specifies how to submit comments and petitions electronically or by mail.

Personalized for You

How does this regulation affect your finances?

Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Key Dates

Published Date
5/19/2025

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
Food and Drug Administration
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register